Dr. Bunn on the MYSTIC Trial for Lung Cancer

Paul A. Bunn Jr, MD
Published: Wednesday, Aug 30, 2017



Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Further details are needed from this trial in order to come to a conclusion regarding its results, states Bunn.

This study did not meet its primary endpoint of progression-free survival, explains Bunn. The study investigated chemotherapy versus durvaluamab (Imfinzi) and tremilumumab versus durvalumab alone. There were a number of different subsets that need to be analyzed further.
 


Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the MYSTIC trial for patients with non–small cell lung cancer (NSCLC).

Further details are needed from this trial in order to come to a conclusion regarding its results, states Bunn.

This study did not meet its primary endpoint of progression-free survival, explains Bunn. The study investigated chemotherapy versus durvaluamab (Imfinzi) and tremilumumab versus durvalumab alone. There were a number of different subsets that need to be analyzed further.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x